Validation of biomarkers in Huntington’s disease to support the development of disease-modifying therapies: a systematic review and critical appraisal scheme
Objective: To review studies for disease progression biomarkers published in HD and evaluate their methodological quality in a standardized manner. Background: Huntington disease (HD) is a fatal autosomal dominant neurodegenerative condition that starts to manifest clinically around the 4th decade of life. There are promising novel genetic-based therapies under development intended to modify the disease trajectory. Valid…The impact of gender identity and gender role orientation on health-related quality of life in people with Parkinson’s disease.
Objective: To assess the associations of gender identity and gender role orientation with health-related quality of life (HRQoL) among persons with Parkinson’s disease (PD). Background:…Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan
Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…MDS Translation Program for MDS-UPDRS, UDysRS, and MDS-NMS
Objective: To summarize the status of the ongoing MDS-sponsored translation programs for non-English versions of the MDS-UPDRS, UDysRS, and MDS-NMS. Background: The MDS-UPDRS, UDysRS, and…Passive monitored daily motor behavior significantly relates to quality of life in early Parkinson’s disease
Objective: To investigate whether passively acquired measures of gait and hand gestures are associated with health-related quality of life (HrQoL; PDQ-39) and health-state (EQ-5D-5L) in…A Systematic Review of the Psychometric Properties of Psychosis Rating Scales in Neurodegenerative Conditions
Objective: To provide an overview of psychosis rating scales validated in specific neurodegenerative disease populations and compare psychometric characteristics of the validated psychosis scales. Background:…The Progressive Supranuclear Palsy Clinical Deficits Scale
Objective: To develop a scale to monitor clinical deficits in patients with Progressive Supranuclear Palsy across its broad phenotypes. Background: There is currently no undisputed,…Toward the digitization of the International Parkinson and Movement Disorder Society rating scales
Objective: Create recommendations for the electronic use of rating scales (e-scaled) owned or managed by the International Parkinson and Movement Disorder Society (MDS). Background: Medicine…Clinical and self-reported falls prediction tools in people with Parkinson’s disease
Objective: To externally validate the 3-step clinical prediction tool for identifying people with Parkinson’s disease (PD) at risk of falls; to validate this tool using…Feasibility of video-based motion analysis to rate the severity of tremor and bradykinesia in Parkinson’s disease
Objective: To evaluate the feasibility of video-based motion analysis for rating resting tremor and finger tapping in Parkinson’s disease. Background: Unified Parkinson’s Disease Rating Scale…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 35
- Next Page »